A 18-year clinical follow-up period in a male patient with a germline TSH-R gene mutation (Met453Thr) is described. Nonautoimmune thyrotoxicosis was diagnosed at the age of 7 months. The patient had exophthalmus, failure to thrive, advanced bone age and no goiter. Long-term antithyroid drug treatment (ATD) was necessary during childhood. At the age of 7 years he developed a goiter. Subtotal thyroidectomy was performed at the age of 9 years, followed by repeated ablative radiotherapy at the age of 9.5–13 years due to a toxic multinodular goiter. After 13 years ATD could be discontinued and the patient was euthyroid until 16 years of age, where L-thyroxine substitution had to be started. The exophthalmus diminished, and had disappeared at the age of 18 years, when CT scan of the orbit was performed. Conclusion: TSH-R mutation must be considered in early nonautoimmune thyrotoxicosis. A very agressive treatment strategy is necessary.

1.
Zakarija M, McKenzie JM, Hoffman WH: Prediction and therapy of intrauterine and late onset neonatal hyperthyrodism. J Clin Endocrinol Metab 1986;62:368–371.
2.
Roux N, Polak M, Couet J, Leger J, Czernichow P, Milgrom E, Misrahi M: A neomutation of the thyroid-stimulating hormone receptor in a severe neonatal hyperthyroidism. J Clin Endocrinol 1996;81:2023–2026.
3.
Kopp P, Van Sande J, Parma J, Duprez L, Gerber H, Joss E, Jameson JL, Dumont JE, Vassart G: Brief Report: Congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene. N Engl J Med 1995;332:150–154.
4.
Duprez L, Parma J, van Sande J, Allgeier A, Leclere J, Schvartz C, Delisle MJ, Decoulx M, Orgiazzi J, Dumont J, Vassart G: Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nature Genetics 1994;7:396–401.
5.
Holzapfel HP, Wonerow P, Petrykowski W, Henschen M, Scherbaum WA, Paschke R: Sporadic congenital hyperthyroidism due to a spontanous germline mutation in the thyrotropin receptor gene. J Clin Endocrinol Metab 1997;82:3879–3884.
6.
Kopp P, Muirhead S, Jourdain N, Gu WX, Jameson JL, Rodd C: Congenital hyperthyroidism caused by a solitary toxic adenoma harboring a novel somatic mutation (Serine281Isoleucine) in the extracellular domain of the thyrotropin receptor. J Clin Invest 1997;100:1634–1639.
7.
Tonacchera M, van Sande J, Parma J, Duprez L, Cetani F, Costagliola S, Dumont JE, Vassart G: TSH receptor and disease. Clin Endocrinol 1996;44:621–633.
8.
Tonacchera M, van Sande J, Cetani F, Swillens S, Schvartz C, Winiszewski P, Portmann L, Dumont JE, Vassart G, Parma J: Functional characteristics of three new germline mutations of the thyrotropin receptor gene causing autosomal dominant toxic thyroid hyperplasia. J Clin Endocrinol Metab 1996;81:547–554.
9.
Vassart G, Georges M, Monsieur R, Brocas H, Lequarre AS, Christophe D: A sequence in M13 phage detects hypervariable minisatellites in human and animal DNA. Science 1987;235:683–684.
10.
Vitti P, Elisei R, Tonacchera L, Chiovato L, Mancusi F: Detection of thyroid-stimulating antibody using Chinese hamster ovary cells transfected with cloned human thyrotropin receptor. J Clin Endocrinol Metab 1993;76:499–503.
11.
Andersen E, Hutchings B, Jansen J, Nyholm M: Heights and weights in Danish children. Ugeskrift Læger 1982;144:1760–1765.
12.
Vassart G, Dumont JE: The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr Rev 1992;13:596–611.
13.
Drexhage HA: Autoimmunity and thyroid growth: Where do we stand? Eur J Endocrinol 1996;135:39–45.
14.
Parma J, Duprez L, Van Sande J, Hermans J, Rocmans P, Van Vliet G, Constagliola S, Rodien P, Dumont JE, Vassart G: Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alfa genes as a cause of toxic thyroid adenomas. J Clin Endocrinol Metab 1997;82:2695–2701.
15.
Thomas J, Lecklere J, Hartemann P, Duhille J, Orgiazzi J, Petersen M, Janot C, Guedemnet JG: Familial hyperthyroidism without evidence of autoimmunity. Acta Endocrinol 1982;100:512–518.
16.
Franklyn JA: Graves ophthalmopathy and the TSH receptor. Lancet 1993;342:318–319.
17.
Stadlmayr W, Spitzweg C, Bichlmair AM, Heufelder AE: TSH receptor transcripts and TSH receptor-like immunoreactivity in orbital and pretibial fibroblasts of patients with Graves’ ophthalmopathy and pretibial myxedema. Thyroid 1997;7:3–12.
18.
De Groot LJ, Larsen PRN, Hennemann G: The Thyroid and Its Disorders, ed 6. New York, Churchill-Livingstone, 1996.
19.
Clark JD, Gelfand MJ, Elgazzar AH: Iodine-131 therapy of hyperthyroidism in pediatric patients. J Nucl Med 1995;36:442–445.
20.
Lavard L, Ranløv I, Perrild H, Andersen O, Jacobsen BB: Incidence of juvenile thyrotoxicoses in Denmark 1982–88. Eur J Endocrinol 1994;130:565–568.
21.
Perrild H, Jacobsen BB: Thyrotoxicosis in childhood. Eur J Endocrinol 1996;134:678–679.
22.
Levy WJ, Schumacher P, Gupta M: Treatment of childhood Graves’ disease. Cleveland Clin J Med 1988;55:373–382.
23.
Perrild H, Gruters-Kieslich A, Feldt-Rasmussen U, Grant D, Martino E, Kayser L, DeLange F: Diagnosis and treatment of thyrotoxicosis in childhood. Eur J Endocrinol 1994;131:467–473.
24.
Lippe B, Landaw EM, Kaplan SA: Hyperthyroidism in children treated with long-term medical therapy: Twenty-five percent remission every two years. J Clin Endocrinol. 1987;64:1241–1245.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.